The World Health Organization declared mpox outbreak as a public health emergency of international concern in July 2022 and August 2024. To date, the Philippines has reported 15 confirmed cases. This report described the demographics, clinical presentations, transmission risks, outcome and viral genetic clades of confirmed mpox cases.

Data from six RT-PCR-confirmed cases at the Research Institute for Tropical Medicine identified MPXV clade II in five cases and MPXV clade III in one case. The cases involved five cisgender men who have sex with men (MSM), three of which were known to be people living with HIV (PLHIV) on antiretroviral therapy (ART) and one cisgender female. The median age was 31. Two cases had a history of international travel prior to symptoms.

The cases presented with skin rash (100%), fever (100%), malaise (100%), genital rash (67%), localized lymphadenopathy (16.67%), and headache (16.67%). Skin lesions were umbilicated, presenting as vesicles (100%), papules (83%), or pustules (50%). Secondary bacterial skin infections were reported in two cases. Sequelae included post-inflammatory hyperpigmentation and scarring. No severe complications or deaths occurred.

Mpox outbreak emphasized the threat of emerging and re-emerging infectious diseases. This report provides insights on mpox’ clinical manifestations, transmission, and outcomes in MSM and PLHIV. Mild disease presentations in HIV patients emphasize the importance of ART adherence in preventing severe complications. Despite the small sample size, this study underscores the need for ongoing surveillance and targeted public health intervention focusing on awareness, safe sexual practices, early diagnosis and treatment.